Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2486216 | 1.00 | SLC10A2 (0.72) | SLC10A2 | |
| SCHEMBL2486212 | 1.00 | SLC10A2 (0.72) | SLC10A2 | |
| SCHEMBL8225837 | 1.00 | SLC10A2 (0.72) | SLC10A2 | |
| SCHEMBL2457392 | 0.91 | SLC10A2 (0.77) | SLC10A2 | |
| SCHEMBL9961456 | 0.91 | SLC10A2 (0.77) | SLC10A2 | |
| SCHEMBL2457393 | 0.91 | SLC10A2 (0.77) | SLC10A2 | |
| SCHEMBL22285894 | 0.91 | SLC10A2 (0.77) | SLC10A2 | |
| SCHEMBL1361642 | 0.91 | SLC10A2 (0.74) | SLC10A2 | |
| SCHEMBL2946578 | 0.91 | SLC10A2 (0.74) | SLC10A2 | |
| SCHEMBL1361639 | 0.91 | SLC10A2 (0.74) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360127-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2025-11-27 | — | — | US | disclosed |
| US-20220160726-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2022-05-26 | — | — | US | disclosed |
| CN-114096268-A | Methods for increasing growth in pediatric subjects with cholestatic liver disease | 米鲁姆制药公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-114072153-A | Methods for treating cholestasis | 米鲁姆制药公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-114072152-A | Genotype and dose-dependent response to ASBTI in patients with bile salt efflux pump deficiency | 米鲁姆制药公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-107375932-B | Bile acid recirculation inhibitor for treating children cholestatic liver disease | 夏尔人类遗传性治疗公司 | 2021-12-21 | — | — | CN | disclosed |
| US-20210113585-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-20200246366-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | LUMENA PHARMACEUTICALS LLC (US) | 2020-08-06 | — | — | US | disclosed |
| EP-0971744-A2 | COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998040375-A2 | COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360127-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | SLC10A2 2/4885 |
| US-20200246366-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885 |
| US-20210113585-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | SLC10A2 2/4885 |
| US-20220160726-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | SLC10A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.